We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Rapid Tests Available for Clostridium Difficile

By HospiMedica staff writers
Posted on 14 Jun 2006
Two enzyme immunoassays and a rapid card format test provide rapid and accurate detection of the toxinotype III strain of Clostridium difficile. More...
This strain was responsible for recent outbreaks of diarrhea in hospitals in the United States, the United Kingdom, and the Netherlands.

The toxinotype III strain appears to have heightened virulence as well as some antibiotic resistance, which make treatment more difficult. Hospitals in the United States have reported cases of C difficile in patients not thought to be at risk for developing this traditionally nosocomial infection. Because the strain has led to increased morbidity and mortality among patients, the need for early detection and isolation has increased.

The cytotoxin test traditionally used to detect this strain is highly sensitive, but results are not available for 24-72 hours. Meridian Bioscience (Cincinnati, OH, USA) offers several assays for detection of the C difficile common antigen or its toxins. The Premier toxins A&B kit is a sensitive, specific microwell assay designed for high-volume laboratories. The Premier kit has a sensitivity of 94.7% and provides results within 60 minutes.

Meridian Bioscience also offers ImmunoCard toxins A&B, which is a rapid card-format test that has a 98% correlation with cytotoxin testing. ImmunoCard results are available in approximately 15 minutes.



Related Links:
Meridian Bioscience

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Monitor/Defibrillator
Zenix
Radiofrequency Generator
GX1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.